🇺🇸 FDA

Intelligence · Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
18,156
Companies
1,062
Drugs tracked
3,385

Quick answer

NovaPharmaNews tracks 18,156 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.

163 results for “Ark” Clear

  1. MRx0029

    4D Molecular Therapeutics

    Idiopathic Parkinson Disease

    phase 1 mab terminated

    1 trial

  2. MT-401-OTS

    Marker Therapeutics

    Acute Myeloid Leukemia, in Relapse

    phase 1 small molecule active

    1 trial

  3. MT-601

    Marker Therapeutics

    Non-Hodgkin Lymphoma, Adult

    phase 1 small molecule active

    1 trial

  4. MT-601 dose 200 million cells

    Marker Therapeutics

    Pancreas Cancer

    phase 1 small molecule active

    1 trial

  5. N-acetylcysteine

    Ultragenyx UK Limited

    Parkinson's Disease

    phase 1 small molecule completed

    1 trial

  6. Open label, single-center, cross-over randomized, relative bioavailability study comparing a new pitolisant hydrochloride tablet formulation versus the marketed pitolisant (Wakix®) tablet formulation after single oral administrations in healthy subjects.

    Bioprojet Pharma

    narcolepsy with cataplexy, Narcolepsy

    phase 1 other active

    1 trial

  7. Open label, single-center, cross-over randomized, relative bioavailability study comparing a new pitolisant hydrochloride tablet formulation at 4 different strengths versus the marketed pitolisant (Wakix®) tablet formulation after single oral administrations in healthy subjects

    Bioprojet Pharma

    Narcolepsy, Narcolepsy with cataplexy

    phase 1 other active

    1 trial

  8. Opicapone

    NEUROCRINE BIOSCIENCES INC

    Parkinson Disease

    phase 1 small molecule completed

    1 trial

  9. Phase I, Open-Label Study to Evaluate the Pharmacokinetics, Safety and Tolerability of BIA 28-6156 in Participants with Varying Degrees of Renal Impairment

    Bial Portela & Companhia S.A.

    Parkinson's disease

    phase 1 other active

    1 trial

  10. Phase Ib Safety, Tolerability and Pharmacokinetic Study of Subcutaneously Administered HER-096 in Healthy Volunteer Subjects and Patients with Parkinson’s Disease

    Pharma Mar S.A.

    Parkinson’s Disease

    phase 1 other active

    1 trial

  11. Pimavanserin

    Acadia Pharmaceuticals B.V.

    Parkinson Disease

    phase 1 small molecule terminated

    1 trial

  12. Pramipexole

    United Therapeutics Europe Ltd

    Parkinson Disease

    phase 1 small molecule completed

    1 trial

  13. Randomised, bioequivalence clinical trial of rasagiline 1 mg capsules vs rasagiline 1 mg tablets, after a single oral dose administration to healthy volunteers under fasting conditions in crossover replicated design.

    Laboratorios Tillomed Spain S.L.U

    Parkinson´s disease

    phase 1 other active

    1 trial

  14. SER-214

    Serina Therapeutics

    Parkinson's Disease

    phase 1 small molecule active

    1 trial

  15. SER-252 (PEOZ-apomorphine)

    Serina Therapeutics

    PARKINSON DISEASE (Disorder)

    phase 1 small molecule active

    1 trial

  16. Sativex(Registered Trademark)

    BRIGHT MINDS BIOSCIENCES INC.

    Cannabis

    phase 1 small molecule completed

    1 trial

  17. UB-312

    BRIGHT MINDS BIOSCIENCES INC.

    Parkinson's Disease

    phase 1 mab completed

    1 trial

  18. VY-AADC01

    NEUROCRINE BIOSCIENCES INC

    Parkinson's Disease

    phase 1 mab completed

    1 trial

  19. VY-AADC01

    NEUROCRINE BIOSCIENCES INC

    Idiopathic Parkinson's Disease

    phase 1 small molecule completed

    1 trial

  20. VY-AADC02

    NEUROCRINE BIOSCIENCES INC

    Parkinson's Disease

    phase 1 mab completed

    1 trial

  21. [123I] IBVM and SPECT imaging

    United Therapeutics Europe Ltd

    Parkinson Disease

    phase 1 small molecule completed

    1 trial

  22. APOKYN

    SUPERNUS PHARMACEUTICALS, INC.

    Parkinson's Disease

    approved small molecule terminated

    2 trials

  23. Biomarker

    United Therapeutics Europe Ltd

    Transplantation, Liver

    approved gene therapy terminated

    1 trial

  24. CREXONT ER

    Amneal Pharma Europe Ltd

    Parkinson Disease

    approved small molecule active

    2 trials

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 18,156 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources